Pharmacyclics planning offering

Pharmacyclics Inc. (NASDAQ:PCYC) proposed to raise up to $24 million in a rights issue. The company's PCI-24781 is an HDAC inhibitor that is in a Phase I trial to treat advanced solid tumors and in a ...